Clinic timetabel

The Department of Rheumatology and Immunology, Beijing University People's Hospital, is one of the first rheumatology centers established in China (1983). It was credited as Excellence in Clinical Immunology by the Department of Education of China . In the Department of Rheumatology, there are 4 Professors and 5 A/Professors, 5 Attending Rheumatologists, 3 residents, 15 nurses and 3 laboratory staffs and over 20 PhD, Master and Post-doctoral researchers.

Positions

Titles hold by the Professors in the department, include Chief-Editor of Chinese Journal of Rheumatology, Vice President of Chinese Rheumatology Association, Vice President of Clinical Immunology Association of China, International member of ACR, Board Members of the National Science Foundation, and Board Members of Sino-Food Drug Administration (SFDA). Several professors are respectively, the reviewer or Editor Board Members of “Scand J Immunol”, “Clin Rheumtol”, “lupus”, Chi Med J (English edition), Chi J Intern Med, Chi Med J, Chi J Rheumatol and Chi J Pract Intern Med.

Scientific Exchanges

The Department of Rheumatology and Immunology has taken a number of visiting rheumatology fellows and researchers from all over the country for advanced clinical and lab training. The department has hosted many visiting Professors and rheumatologists from the USA , Australia , UK , Switzerland , Canada , Norway and Japan etc.

Clinics & novel diagnostic therapeutic achievements

There are more than 25 thousand out-patients per year with 36 in -patient beds in the department. We have developed over 20 new serological and genetic markers in diagnosis of rheumatic diseases. More than 10 novel immune-based therapies have been used for refractory rheumatoid arthritis, systemic lupus erythematosus and Sjogren Syndrome, including T cell vaccination for SLE, immune ablation (such as immune-adsorption, double plasma filtration etc.) for RA, SLE and Sjogren syndrome. The other therapies include small pulse cyclophosphamide therapy for SLE, SS and PM, 99Tc-MDP and many bioagents (Enternercept, Remicade) for RA. Some of these diagnostic and therapeutic approaches are leading techniques in China as well as in the world.

THE GRANTS THAT WE HAVE GAINED:

In the last several years, 16 national and local government research projects and programs have been granted to this department with over ￥ 11 millions (US$ 1,700,000). These include:

•  Recognition of antigen and T cell activation in rheumatoid arthritis;

Funded by National Science Foundation;

•  HLA-DRB1 specific peptides and their role in rheumatoid arthritis;

Funded by National Outstanding Youth Foundation

•  Therapeutic CII peptides in CIA;

Funded by National Science Foundation

•  Inhibitory effect of siRNA on HLA-DR4 expression in rheumatoid arthritis;

Funded by Peking University People's Hospital Foundation

•  Non-T cell stimulating peptide in HLA-DRB1 restricted T cell responses;

Funded by National Science Foundation (the Grant Project)

•  Screening of new antigens in Sjogren syndrome using salivary cDNA library;

Funded by Cross-century Talent Fund of National Education Department of China

•  Identification of newly found proteins in RA synovium and sera ;

Funded by Chinese peptides and proteins in RA

•  Citrullinated peptides and proteins in RA;

Funded by National Science Foundation

•  Antigenic epitopes of a-fodrin/M3 receptor and application in the diagnosis of Sjogren's Syndrome;

Funded by Beijing Nature and Science Foundation

•  Inhibition of T cell expression using siRNA

Founded by “863” project.

•  Intercellular expression of altered CII peptides and their role in inhibition of T cell activation in RA;

Funded by National Science Foundation

•  T cell vaccination in SLE;

Funded by Beijing Science Bureau

•  TCR-Vb analogues in TCR mediated T cell activation;

Funded by National Science Foundation

…etc.